KCP
AZN icon

Kera Capital Partners’s AstraZeneca AZN Stock Holding History

Kera Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Sell
1,434
-687
-32% -$129K 0.03% 522
2026
Q1 		$418K Sell
2,121
-221
-9% -$42.6K 0.05% 305
2025
Q4 		$435K Buy
+2,342
New +$411K 0.05% 287

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Kera Capital Partners's AZN Position: Q2 2026 in Review

Kera Capital Partners reduced its AstraZeneca (AZN) stake by 32% in Q2 2026, selling an estimated $129K and leaving 1,434 shares worth $272K. The position accounts for 0.03% of the portfolio, ranked #522.

Kera Capital Partners first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $435K in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Kera Capital Partners held 1,434 shares of AstraZeneca worth $272K as of Q2 2026.
  • Kera Capital Partners sold 687 AstraZeneca shares in Q2 2026, an estimated $129K.
  • AstraZeneca made up 0.03% of Kera Capital Partners's portfolio in Q2 2026, its #522 holding.
  • Kera Capital Partners first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • Kera Capital Partners's AstraZeneca position peaked at $435K in Q4 2025.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Kera Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.